AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)


This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase. When the level of disease is very low, it's called molecular remission. TKIs are a type of medication that help keep this level low. However, after being in molecular remission for a specific amount of time, it may not be necessary to take tyrosine kinase inhibitors. It is not yet known whether stopping tyrosine kinase inhibitors will help patients with chronic myeloid leukemia in chronic phase continue or re-achieve molecular remission.

I'm interested

Male or Female
Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• < 25 years old
• diagnosis of CML-CP before age 18
• patient must be in molecular remission (MR) for ? 2 consecutive years at the time of enrollment
• patient must have received any TKI for a minimum of 3 consecutive years and agree to stop using TKI therapy
• see link to for complete criteria
Exclusion Criteria:

• known T3151 mutation
• history of accelerated phase or blast crisis CML
• women who are pregnant
• if breast feeding, must agree to stop

Procedure: Biospecimen Collection, Other: Drug Withdrawn, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Drug: Tyrosine Kinase Inhibitor


BCR-ABL1 Positive, Chronic Phase Chronic Myeloid Leukemia, CML-CP, Leukemia

Allison Fullenkamp -
Peter Gordon
See this study on